MedTrace Logo

Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)

NCT05841862 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-06-12

No results posted yet for this study

Summary

Pilot, randomized, observer and participant masked, sham and fellow eye controlled, interventional clinical device trail to evaluate the safety and effectiveness of the 2C-QD device to improve visual function in adults with advanced Retinitis Pigmentosa (RP).

Conditions

Interventions

DEVICE

2C-QD

Quantum Dot

DEVICE

Sham 2C-QD

Sham Intravitreal Injection

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • 2C Tech Corp

    lead INDUSTRY

Principal Investigators

  • Timothy Jackson, Professor · Kings College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2025-03-31
Completion
2025-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05841862 on ClinicalTrials.gov